
This dataset shows 2025 Medicare Advantage enrollment by parent organization. Each row lists a carrier, the number of covered lives in its MA products, its share of the national MA market, and the cumulative share when ranked from largest to smallest. Source fields document whether the figure comes from KFF’s July 2025 national enrollment update or from CMS’s August 2025 Monthly Enrollment by Contract file.
medicare advantage, spravato, ketamine therapy, Medicare, iv ketamine
medicare advantage, spravato, ketamine therapy, Medicare, iv ketamine
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
